Actively Recruiting
The Relationship Between Myonectin Concentration and the Course of ST-segment Elevation Myocardial Infarction
Led by Michał Jaśkiewicz · Updated on 2024-04-30
100
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
Sponsors
M
Michał Jaśkiewicz
Lead Sponsor
J
Jan Biziel University Hospital No 2 in Bydgoszcz
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this study is to test the potentially protective role of myonectin in patients with a first episode of ST elevation myocardial infarction (MI) treated with primary percutaneous coronary intervention (PCI). The main questions which are assumed to be answered after study completion: 1. Does higher myonectin concentration influence the in-hospital and 30-day course of the first ST-elevation MI in patients treated with primary coronary angioplasty 2. Is there a relationship between the serum myonectin concentration, related to patient's nutritional status and physical activity with the patient's physical activity declared as usually before the coronary event occurrence, the cardiac biomarkers level, and myocardial and skeletal muscle mass determined in order to objectify the relationship of physical activity before the infarction with 30-day and one-year mortality, and the other primary and secondary outcomes measured at 12-month visit, e.g. the extent of myocardial infarction, 3. Is there a relationship between the baseline concentration of myonectin and troponin with the control of atherosclerosis risk factors, declared physical activity and parameters of body composition, outcome of treadmill exercise test, values of echocardiographic parameters and myonectin concentration 12 months after a cardiovascular incident
CONDITIONS
Official Title
The Relationship Between Myonectin Concentration and the Course of ST-segment Elevation Myocardial Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Symptoms of acute coronary syndrome
- Acute ST segment elevation in two or more leads on ECG
- Undergoing primary percutaneous coronary intervention (PCI)
You will not qualify if you...
- Pregnancy
- Unconsciousness, altered consciousness, or inability to cooperate
- Cardiogenic shock
- Significant physical effort within 24 hours before MI onset
- Active infection at admission or recent intramuscular injection
- History of myocardial infarction
- Heart failure New York Heart Association (NYHA) class III or IV
- Renal failure with glomerular filtration rate (GFR) less than 30 ml/min
- History of malignant neoplasms within the last 5 years
- Being legally incapacitated, active soldiers, imprisoned, or related to study investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Voivodeship Hospital in Elblag
Elblag, Warmian-Masurian Voivodeship, Poland, 82-300
Actively Recruiting
Research Team
M
Michał Jaśkiewicz, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here